The clinical manifestation of this interference is Cushing syndrome, which is one of leading dose-limiting factors for glucocorticoids [ 1, 26].
The inclusion criteria for randomisation were completion of the run-in period: without evidence of disease progression (PD); without grade ⩾2 rash development; or without development of toxicity leading to dose adjustments <75% of the full chemotherapy dose.
Neutropenia, leukopenia, and peripheral neuropathy were the most common TRAEs leading to dose interruption (in 13, 4, and 3 patients, respectively); dose reductions were most commonly due to neutropenia and peripheral neuropathy (in 12 and 7 patients, respectively).
Twycross [ 18] advocated the use of a clear plan when corticosteroids were being administered, including regular monitoring leading to dose adjustment, and prescribing for the shortest time frame at the lowest effective dose [ 18].
It may be that the breaks in CRRT are not adjusted for in the prescribed dose, leading to under-dosing.
cAE leading to dose reduction.
Severe toxicities occurred more frequently than expected, leading to dose modifications in 39% of the patients.
All AEs leading to dose reduction were related to the study medication, except for one.
The most common adverse event leading to dose reduction was hand foot skin reaction.
Twenty patients (77%) experienced adverse events leading to dose interruption of study drugs after cycle 1.
Overall, five patients experienced AEs leading to dose reductions in pomalidomide.
